Philips Launches RADIQAL Trial to Test Innovative Radiation Reduction Technology
Royal Philips has officially launched the RADIQAL (Radiation Dose and Image Quality Trial), a multicenter, randomized study aiming to enroll 824 patients with coronary artery disease (CAD) across six hospitals in Spain, Czech Republic, and the United States. The first participant was successfully enrolled at Aarhus University Hospital in Denmark.
Dr. Javier Escaned, a leading cardiology expert and principal investigator at Hospital Clínico San Carlos, emphasized the importance of reducing radiation exposure in interventional cardiology. "Achieving high-quality angiograms while utilizing diluted contrast media is crucial," he noted. The RADIQAL trial will explore whether Philips’ new ultra-low X-ray dose technology can significantly cut down radiation exposure for both patients and medical staff, without compromising the quality of coronary interventions.
CAD, the most common heart disease globally, results from chronic inflammation of coronary arteries, leading to potential blockages and severe health risks. Percutaneous coronary intervention (PCI) is a minimally invasive procedure that aims to open blocked arteries and treat this condition. The Philips Azurion system, designed for real-time X-ray imaging during such procedures, plays a pivotal role in this context.
The RADIQAL trial will compare the new ultra-low dose technology with the existing ClarityIQ technology, both integrated into the Azurion system. The innovative technology reportedly reduces X-ray exposure by 50% compared to the current best settings. This advancement has already received CE marking under the EU MDR regulatory framework, although it is not yet cleared in FDA-regulated countries, and enrollment in the U.S. has not commenced.
Dr. Darshan Doshi of Philips highlighted that reducing radiation while improving image quality remains a crucial goal in interventional cardiology, particularly for high-risk patients requiring frequent interventions.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
